[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Rupolo M, Berretta M, Buonadonna A, Stefanovski P, Bearz A, Bertola G, Canzonieri V, Morassut S, Frustaci S: Metastatic angiosarcoma of the spleen. A case report and treatment approach. Tumori; 2001 Nov-Dec;87(6):439-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angiosarcoma of the spleen. A case report and treatment approach.
  • We report a case of a 28-year-old man with angiosarcoma of the spleen and liver metastases.
  • The aim of this paper is to underline the importance of planned splenectomy in these patients even if they have metastatic disease, and to propose an intensive chemotherapy regimen consisting of anthracyclines, ifosfamide and mesna with G-CSF support.
  • [MeSH-major] Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Palliative Care. Quality of Life. Splenectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11989602.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Shiba M, Takatera H, Tokizane T, Terakawa T: [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report]. Hinyokika Kiyo; 2003 Aug;49(8):463-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma of the spleen 11 years after chemotherapy for testicular seminoma: a case report].
  • A 32-year-old man who had previously undergone chemotherapy for testicular seminoma 11 years ago was admitted to our hospital with a pain in the right leg.
  • Computed tomography (CT) and bone scintigraphy revealed splenomegaly and multiple bone disease.
  • The pathologic diagnosis of the resected spleen and the biopsied rib was angiosarcoma.
  • We found no reports of angiosarcoma following previous chemotherapy for testicular cancer.
  • It is unclear whether the angiosarcoma is a secondary neoplasm induced by the chemotherapy or not.
  • The chemotherapy might also have affected the chromosomal aberration presumably in endothelial progenitor cells causing the development of a secondary neoplasm.
  • To our knowledge, this is the first case of angiosarcoma after chemotherapy for testicular seminoma.
  • [MeSH-major] Hemangiosarcoma / etiology. Neoplasms, Second Primary / etiology. Seminoma / drug therapy. Splenic Neoplasms / etiology. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518382.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Hamid KS, Rodriguez JA, Lairmore TC: Primary splenic angiosarcoma. JSLS; 2010 Jul-Sep;14(3):431-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic angiosarcoma.
  • Primary splenic angiosarcoma is a rare, aggressive malignant neoplasm arising from splenic vascular endothelium.
  • Splenic enlargement with heterogeneous enhancement was identified on CT of the abdomen.
  • Laparoscopic splenectomy was performed, and a primary splenic angiosarcoma was discovered.
  • After 2 rounds of chemotherapy, a CT scan showed progressive disease with metastasis to the liver and lung.
  • Primary splenic angiosarcoma is almost universally fatal despite treatment.
  • The best chance for survival is early diagnosis and prompt splenectomy prior to splenic rupture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Med Pediatr Oncol. 2003 Jun;40(6):411-2 [12692821.001]
  • [Cites] Radiographics. 2004 Jul-Aug;24(4):1137-63 [15256634.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Med Pediatr Oncol. 1981;9(4):319-24 [7196486.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):702-8 [8310831.001]
  • [Cites] South Med J. 1995 Aug;88(8):873-5 [7631220.001]
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2400-6 [8635113.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):827-35 [9236839.001]
  • [Cites] Radiology. 2005 Apr;235(1):106-15 [15749977.001]
  • [Cites] Pediatr Surg Int. 2007 Aug;23(8):807-10 [17641924.001]
  • [Cites] J Natl Med Assoc. 2000 Mar;92(3):143-6 [10745645.001]
  • (PMID = 21333203.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3041046
  •  go-up   go-down


Advertisement
4. Mutsaers AJ: Metronomic chemotherapy. Top Companion Anim Med; 2009 Aug;24(3):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metronomic chemotherapy.
  • Chemotherapy drugs are usually administered at doses that are high enough to result in an obligatory break period to allow for the observation of potential side effects and institution of supportive care, if required.
  • In recent years, efforts to administer chemotherapy on a more continuous basis, with a much shorter break period, or none at all, have received increased interest, and the practice has come to be known as metronomic chemotherapy.
  • The basis for success with this currently investigational approach may be rooted in continuous drug exposure to susceptible cancer cells, inhibition of tumor blood vessel growth-a process known as tumor angiogenesis, and/or alterations in tumor immunology.
  • Increased benefit also appears to occur when metronomic chemotherapy is used in combination with newer, targeted antiangiogenic agents, and therefore represents a promising approach to combination therapy, particularly as targeted oncology drugs make their way into veterinary oncology applications.
  • There is still much to be learned in this field, especially with regard to optimization of the proper drugs, dose, schedule, and tumor applications.
  • However, the low cost, ease of administration, and acceptable toxicity profiles potentially associated with this therapeutic strategy make metronomic chemotherapy protocols attractive and suitable to veterinary applications.
  • Preliminary clinical trial results have now been reported in both human and veterinary medicine, including adjuvant treatment of canine splenic hemangiosarcoma and incompletely resected soft tissue sarcoma, and, further, more powerful studies are currently ongoing.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dog Diseases / drug therapy. Sarcoma / veterinary. Soft Tissue Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Drug Administration Schedule

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732732.001).
  • [ISSN] 1938-9736
  • [Journal-full-title] Topics in companion animal medicine
  • [ISO-abbreviation] Top Companion Anim Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 56
  •  go-up   go-down


5. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • Primary angiosarcomas of the spleen are rare and almost always fatal.
  • The mean age of patients at presentation is 59 years and the major clinical findings include abdominal pain, splenic rupture, and splenomegaly.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • The worst prognostic factor is splenic rupture with early metastasis.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


6. Sorenmo K, Duda L, Barber L, Cronin K, Sammarco C, Usborne A, Goldschmidt M, Shofer F: Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med; 2000 Jul-Aug;14(4):395-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine hemangiosarcoma treated with standard chemotherapy and minocycline.
  • Standard treatments for canine hemangiosarcoma include surgery and chemotherapy with doxorubicin, but in spite of treatment most dogs with this disease die within 6 months of diagnosis.
  • Antiangiogenic drugs such as minocycline may provide therapeutic benefits in cancer patients.
  • The purpose of this prospective study was to evaluate the efficacy of chemotherapy with doxorubicin and minocycline, an antiangiogenic agent, in dogs with hemangiosarcoma.
  • Eighteen dogs with histologically confirmed hemangiosarcoma of any stage were treated with doxorubicin, cyclophosphamide, and minocycline.
  • Complete staging was performed before and during the treatment period to assess remission status and response to therapy.
  • No statistically significant difference was found in survival between the dogs treated with chemotherapy and minocycline, and historical controls consisting of dogs that received chemotherapy alone.
  • Postmortem examination revealed widespread metastasis, suggesting that minocycline is ineffective as a single antiangiogenic agent in canine hemangiosarcoma.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Vet Intern Med. 2000 Jul-Aug;14(4):392-4 [10935888.001]
  • (PMID = 10935889.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Bacterial Agents; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FYY3R43WGO / Minocycline
  •  go-up   go-down


7. Hara T, Tsurumi H, Kasahara S, Ogawa K, Takada J, Imai K, Takai K, Kitagawa J, Kiyama S, Imai N, Oyama M, Takami T, Moriwaki H: Long-term survival of a patient with splenic angiosarcoma after resection, high-dose chemotherapy, and autologous peripheral blood stem cell transplantation. Intern Med; 2010;49(20):2253-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with splenic angiosarcoma after resection, high-dose chemotherapy, and autologous peripheral blood stem cell transplantation.
  • FDG-PET revealed a hot spot in the whole spleen.
  • Histological examination was typical for angiosarcoma.
  • Adjuvant chemotherapy was given, and high-dose chemotherapy with autologous peripheral blood stem cell transplantation was performed.
  • Thrombocytopenia developed again in 2008.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / therapy. Peripheral Blood Stem Cell Transplantation. Splenectomy. Splenic Neoplasms / therapy
  • [MeSH-minor] Catheter Ablation. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Fatal Outcome. Female. Hepatectomy. Humans. Interleukin-3 / therapeutic use. Middle Aged. Prednisone / administration & dosage. Recombinant Proteins / therapeutic use. Thrombocytopenia / etiology. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20962445.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-3; 0 / Recombinant Proteins; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW: Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med; 2007 Jan-Feb;21(1):113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
  • BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor of dogs.
  • At present, adjuvant chemotherapy is the only proven effective treatment for dogs with HSA, though the benefits from chemotherapy are modest.
  • Administration of immunotherapy together with chemotherapy has also been reported to improve survival in dogs with HSA.
  • Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA.
  • HYPOTHESIS: That tumor vaccination could be safely and effectively combined with doxorubicin chemotherapy for treatment of dogs with HSA.
  • Dogs received a series of 8 immunizations administered over a 22-week period, and most also received chemotherapy.
  • Clinical adverse effects were noted, immune responses were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, and survival times were calculated.
  • RESULTS: The most common adverse effects observed in vaccinated dogs also treated with doxorubicin chemotherapy were diarrhea and anorexia.
  • Thirteen dogs with stage II splenic HSA that received the tumor vaccine plus doxorubicin chemotherapy had an overall median survival time of 182 days.
  • CONCLUSIONS: We conclude that an allogeneic tumor lysate vaccine is safe in dogs with HSA and can elicit humoral immune responses in dogs that are receiving concurrent doxorubicin chemotherapy.


9. Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med; 2007 Jul-Aug;21(4):764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
  • BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs.
  • At present, conventional adjuvant chemotherapy provides only a modest survival benefit for treated dogs.
  • Continuous oral administration of low-dose chemotherapy (LDC) has been suggested as an alternative to conventional chemotherapy protocols.
  • Therefore, we evaluated the safety and effectiveness of LDC using a combination of cyclophosphamide, etoposide, and piroxicam as adjuvant therapy for dogs with stage II HSA.
  • HYPOTHESIS: We hypothesized that oral adjuvant therapy with LDC could be safely administered to dogs with HSA and that survival times would be comparable to those attained with conventional doxorubicin (DOX) chemotherapy.
  • ANIMALS: Nine dogs with stage II splenic HSA were enrolled in the LDC study.
  • Treatment outcomes were also evaluated retrospectively for 24 dogs with stage II splenic HSA treated with DOX chemotherapy.
  • METHODS: Nine dogs with stage II splenic HSA were treated with LDC over a 6-month period.
  • Adverse effects and treatment outcomes were determined.
  • Overall survival times and disease-free intervals were compared between the 9 LDC-treated dogs and 24 DOX-treated dogs.
  • RESULTS: Dogs treated with LDC did not develop severe adverse effects, and long-term treatment over 6 months was well-tolerated.
  • Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days.
  • By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.
  • CONCLUSIONS: Continuous orally administered LDC may be an effective alternative to conventional high-dose chemotherapy for adjuvant therapy of dogs with HSA.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708397.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA86224-01; United States / NCRR NIH HHS / RR / RR00707
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down


10. Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med; 2000 May-Jun;14(3):271-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ifosfamide for treatment of various canine neoplasms.
  • Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma.
  • Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days.
  • No dog developed clinical or microscopic evidence of hemorrhagic cystitis.
  • Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830540.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


11. den Hoed ID, Granzen B, Granzen B, Aronson DC, Pauwels P, de Kraker J, van Heurn LW: Metastasized angiosarcoma of the spleen in a 2-year-old girl. Pediatr Hematol Oncol; 2005 Jul-Aug;22(5):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasized angiosarcoma of the spleen in a 2-year-old girl.
  • Primary angiosarcoma of the spleen is rare and the prognosis is very poor.
  • The authors present a 2-year-old girl with spontaneous rupture of splenic angiosarcoma.
  • At diagnosis there were liver metastases.
  • After splenectomy she received chemotherapy with ifosfamide, vincristine, and actinomycine D combined with a partial liver resection.
  • She remained in complete remission over 2 years from diagnosis.
  • [MeSH-major] Hemangiosarcoma / secondary. Liver Neoplasms / secondary. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Female. Hepatectomy. Humans. Neoplasm Metastasis. Prognosis. Remission Induction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020128.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Berretta M, Rupolo M, Buonadonna A, Canzonieri V, Brollo A, Morra A, Berretta S, Bearz A, Tirelli U, Frustaci S: Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature. J Chemother; 2006 Apr;18(2):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic angiosarcoma of the kidney: a case report with treatment approach and review of the literature.
  • Angiosarcomas are rare soft tissue malignancies.
  • We report the case of a 67-year-old man affected by a large angiosarcoma of the kidney.
  • After surgical removal, a rapid peritoneal, visceral and cutaneous diffusion developed.
  • Palliative chemotherapy, based on anthracycline and ifosfamide, which are normally used to treat all other high-grade spindle cell sarcomas, was totally inactive.
  • On the basis of these results and of the biological characteristics of these rare neoplasms it is mandatory to develop other therapeutic approaches.
  • [MeSH-major] Hemangiosarcoma / drug therapy. Hemangiosarcoma / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery
  • [MeSH-minor] Aged. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Humans. Ifosfamide / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Nephrectomy. Palliative Care. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736893.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anthracyclines; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Koutelidakis IM, Tsiaousis PZ, Papaziogas BT, Patsas AG, Atmatzidis SK, Atmatzidis KS: Spleen rupture due to primary angiosarcoma: a case report. J Gastrointest Cancer; 2007;38(2-4):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spleen rupture due to primary angiosarcoma: a case report.
  • A case of a 79-year-old female with rupture of the spleen due to primary angiosarcoma is presented.
  • Diagnosis was based on histology postoperatively.
  • Primary angiosarcoma of the spleen is a very rare and aggressive neoplasm with a high metastatic rate and almost uniformly fatal.
  • Due to small number of reported cases, there are no guidelines concerning adjuvant or palliative treatment or any beneficial protocols of chemotherapy or radiotherapy up to date.
  • [MeSH-major] Hemangiosarcoma / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology
  • [MeSH-minor] Aged. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Chirurg. 2004 Jan;75(1):70-4 [14740131.001]
  • [Cites] N Z Med J. 2004 Oct 08;117(1203):U1103 [15477927.001]
  • [Cites] Acta Biomed Ateneo Parmense. 2000;71(5):135-40 [11450114.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Radiology. 2005 Apr;235(1):106-15 [15749977.001]
  • [Cites] J Natl Med Assoc. 2000 Mar;92(3):143-6 [10745645.001]
  • [Cites] J Surg Oncol. 2005 Dec 15;92(4):312-6 [16299797.001]
  • [Cites] AJR Am J Roentgenol. 1982 May;138(5):965-6 [6979189.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Rev Med Interne. 2000 Sep;21(9):809-11 [11039181.001]
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):283-5 [10823452.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):951-9 [14674062.001]
  • [Cites] Ulus Travma Acil Cerrahi Derg. 2007 Oct;13(4):313-5 [17978914.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1054-6 [16048401.001]
  • (PMID = 19016352.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Payne SE, Rassnick KM, Northrup NC, Kristal O, Chretin JD, Cotter SM, Kintzer P, Frimberger AE, Morrison-Collister KE, Wood CA, Moore AS: Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin. Vet Comp Oncol; 2003 Dec;1(4):171-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin.
  • A retrospective analysis was done to assess the toxicity and efficacy associated with an alternating chemotherapy protocol of ifosfamide (375 mg m(-2)) and doxorubicin (30 mg m(-2)) for adjuvant treatment of 39 dogs with sarcomas.
  • Twelve dogs had various soft-tissue sarcomas and 27 dogs had hemangiosarcoma (HSA).
  • One dog had grade 4 neutropenia (<500 microL(-1)) after treatment with ifosfamide and one dog had grade 3 neutropenia (500-1000 microL(-1)) after treatment with doxorubicin.
  • The median survival time (ST) for the 27 dogs with HSA treated by surgery and with doxorubicin/ifosfamide was 149 days (mean 366 days).
  • Although the protocol of alternating ifosfamide and doxorubicin was well tolerated, it failed to result in a statistically significant improvement in the ST when compared to a historical population of dogs with stage 2 splenic HSA treated by surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379178.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Hsu JT, Chen HM, Lin CY, Yeh CN, Hwang TL, Jan YY, Chen MF: Primary angiosarcoma of the spleen. J Surg Oncol; 2005 Dec 15;92(4):312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary angiosarcoma of the spleen.
  • BACKGROUND AND OBJECTIVES: Primary splenic angiosarcoma is a very rare and aggressive neoplasm with a high metastatic rate and dismal prognosis.
  • METHODS: The records of all cases of primary splenic angiosarcoma treated at Chang Gung Memorial Hospital from April 1991 to July 2004 were retrospectively reviewed.
  • Hemoperitoneum due to splenic rupture was noted in one patient.
  • Three patients had distant metastasis to the liver (n = 2), bone (n = 1), bone marrow (n = 1), and small bowel (n = 1) at diagnosis.
  • Liver (n = 3), bone (n = 1), and bone marrow (n = 1) metastases were found in four patients after initial therapy.
  • Five of the six cases underwent a splenectomy, one underwent partial hepatectomy, and one received chemotherapy.
  • The respective 1-, 3- and 5-year survival rates were 60%, 40%, and 40%, and the median survival time was 36 months.
  • CONCLUSIONS: The clinical presentations of splenic angiosarcoma were similar to those of previous reports apart from the higher rate of splenomegaly observed in this study.
  • [MeSH-major] Hemangiosarcoma. Splenic Neoplasms
  • [MeSH-minor] Adult. Aged. Child. Disease-Free Survival. Female. Gastrointestinal Hemorrhage / etiology. Hemoperitoneum / etiology. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Splenectomy. Splenic Rupture / etiology. Splenomegaly / etiology. Thrombocytopenia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16299797.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Clifford CA, Mackin AJ, Henry CJ: Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med; 2000 Sep-Oct;14(5):479-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of canine hemangiosarcoma: 2000 and beyond.
  • Canine hemangiosarcoma (HSA) is an aggressive and malignant neoplasia with a grave prognosis.
  • Surgery and chemotherapy have limited success in prolonging survival times and increasing quality of life in dogs with HSA.
  • An understanding of mechanisms of metastasis has led to the development of new treatments designed to delay or inhibit tumor spread.
  • Promising new treatment options include novel delivery systems (inhalation or intracavitary chemotherapy); use of immunomodulators such as liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine; antimetastatic agents such as inhibitors of angiogenesis (interferons, thalidomide), matrix metalloproteinase inhibitors, and minocycline; dietary modifications; and gene therapy.
  • Inhibitors of angiogenesis seem to be safe and, unlike conventional chemotherapy, do not induce drug resistance.
  • Although many of the newer approaches are still under development and review, the use of multimodality therapy incorporating innovative treatment modalities may offer the best therapeutic option for dogs affected with HSA.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11012108.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inhibitors; 0 / Tetracyclines; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 87
  •  go-up   go-down


17. Hai SA, Genato R, Gressel I, Khan P: Primary splenic angiosarcoma: case report and literature review. J Natl Med Assoc; 2000 Mar;92(3):143-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic angiosarcoma: case report and literature review.
  • Angiosarcoma of the spleen is a rare neoplasm.
  • Generally, this cancer has a poor prognosis and prompt splenectomy offers the only cure, as the cancer is poorly responsive to adjuvant chemotherapy.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Int Surg. 1980 Jul-Aug;65(4):369-73 [7194868.001]
  • [Cites] Acta Chir Scand. 1988 Jul-Aug;154(7-8):477-9 [3188797.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):229-42 [6285748.001]
  • [Cites] Ann Surg. 1990 Jan;211(1):34-42 [2294841.001]
  • [Cites] Gastrointest Radiol. 1990 Winter;15(1):43-6 [2298353.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Br J Surg. 1952 Jul;40(159):68-70 [14944798.001]
  • [Cites] South Med J. 1995 Aug;88(8):873-5 [7631220.001]
  • [Cites] Acta Radiol. 1994 Sep;35(5):455-8 [8086253.001]
  • (PMID = 10745645.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2640552
  •  go-up   go-down


18. Wang C, Rabah R, Blackstein M, Riddell RH: Bone marrow metastasis of angiosarcoma. Pathol Res Pract; 2004;200(7-8):551-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow metastasis of angiosarcoma.
  • We report a rare finding of bone marrow metastasis from an angiosarcoma.
  • The patient was a 36-year-old man who initially presented with a high-grade angiosarcoma of the spleen and was treated with splenectomy and chemotherapy.
  • He developed leukoerythroblastic anemia three years after splenectomy.
  • Bone marrow biopsy revealed extensive infiltrate by angiosarcoma with typical features of spindle tumor cells and anastomosing vascular channels.
  • We have found in the literature two other cases of bone marrow metastasis of angiosarcoma, and all these patients had a primary tumor of the spleen.
  • It would seem that splenic angiosarcomas have a virtually unique propensity for infiltration in the bone marrow.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Hemangiosarcoma / secondary. Splenic Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15462503.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / von Willebrand Factor
  • [Number-of-references] 10
  •  go-up   go-down


19. Verge J, Albiol J, Navas M, Martín C: [Primary angiosarcoma of the spleen with liver metastases. Case report and literature review]. Cir Esp; 2005 Jul;78(1):50-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary angiosarcoma of the spleen with liver metastases. Case report and literature review].
  • [Transliterated title] Angiosarcoma primario de bazo con metástasis hepáticas: presentación de un caso y revisión de la bibliografía.
  • Angiosarcomas of the spleen are infrequent tumors that often present with liver metastases.
  • Immunohistochemical markers can aid preoperative diagnosis since radiological and ultrasonographic images are fairly nonspecific.
  • The recommended treatment is splenectomy.
  • The benefits of chemotherapy and radiotherapy have not been clearly demonstrated.
  • [MeSH-major] Hemangiosarcoma / secondary. Hemangiosarcoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Splenic Neoplasms / pathology. Splenic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Splenectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420791.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Muzi MG, Rulli F, Federico F: Angiosarcoma of the spleen mimicking rupture. Case report and literature review. Acta Biomed Ateneo Parmense; 2000;71(5):135-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen mimicking rupture. Case report and literature review.
  • Primary angiosarcoma of the spleen is very rare and only 143 cases have previously been reported.
  • The prognosis is very poor in any case and survival isn't more than two years: wherever the spleen undergoes spontaneous rupture the survival should be less than six months.
  • Patients with or without metastatic disease may be treated by chemotherapy but with poor results.
  • We report the clinical case concerning a 79-years-old man with liver metastases and a 5-cm lesion in the spleen, where a subcapsular rupture was suspected.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450114.001).
  • [Journal-full-title] Acta bio-medica de L'Ateneo parmense : organo della Società di medicina e scienze naturali di Parma
  • [ISO-abbreviation] Acta Biomed Ateneo Parmense
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 25
  •  go-up   go-down


21. Vakkalanka B, Milhem M: Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review. Clin Med Insights Oncol; 2010 Oct 12;4:107-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel as neoadjuvant therapy for high grade angiosarcoma of the spleen: a brief report and literature review.
  • INTRODUCTION: Splenic angiosarcoma is a rare tumor with only a few cases reported in the literature.
  • We report a case of a locally advanced angiosarcoma rendered operable by treatment with Paclitaxel monotherapy.
  • CASE PRESENTATION: A 69 year old female presented with a high grade splenic angiosarcoma, considered inoperable due to the extent of local spread.
  • CONCLUSION: Chemotherapy options for splenic angiosarcoma are not well studied.
  • Paclitaxel as monotherapy is a useful therapeutic option in down staging tumors, facilitating surgical resection and merits further study in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981134.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2956477
  • [Keywords] NOTNLM ; angiosarcoma / paclitaxel / sarcoma / spleen
  •  go-up   go-down


22. Maier A, Bataille F, Krenz D, Anthuber M: [Angiosarcoma as a rare differential diagnosis in spontaneous rupture of the spleen]. Chirurg; 2004 Jan;75(1):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma as a rare differential diagnosis in spontaneous rupture of the spleen].
  • A splenectomy was performed in a 37-year-old woman because of spontaneous rupture of the spleen.
  • Primary angiosarcoma of the spleen was diagnosed postoperatively based on histology.
  • Primary angiosarcoma of the spleen is a very rare neoplasm with disastrous prognosis.
  • Immunohistochemical and ultrastructural examinations are necessary to verify the diagnosis because the histopathological picture of the tumor is variable.
  • Due to the small number of reported cases, there are no guidelines for adjuvant or palliative therapy, and up to today all adjuvant means of radiotherapy and chemotherapy have not improved the prognosis of the patients.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Splenic Neoplasms / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Radiography, Abdominal. Rupture, Spontaneous. Spleen / pathology. Time Factors. Tomography, Spiral Computed. Tomography, X-Ray Computed. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1996 Mar;61(3):170-6 [8637202.001]
  • [Cites] Rontgenpraxis. 1999;52(3-4):137-9 [10522455.001]
  • [Cites] Pathologe. 2001 Sep;22(5):343-8 [11572116.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):300-4 [6894525.001]
  • [Cites] Eur J Surg. 1991 Mar;157(3):215-7 [1678633.001]
  • [Cites] Acta Biomed Ateneo Parmense. 2000;71(5):135-40 [11450114.001]
  • [Cites] Langenbecks Arch Chir. 1997;382(4):226-30 [9445970.001]
  • [Cites] Cancer. 1985 Apr 1;55(7):1625-7 [4038910.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):398-403 [11355176.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):109-14 [12116058.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):978-87 [11007038.001]
  • [Cites] Arch Pathol Lab Med. 1979 Mar;103(3):122-4 [581838.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Mar;14(3):289-92 [10197502.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2400-6 [8635113.001]
  • [Cites] Eur J Surg Oncol. 1998 Apr;24(2):152 [9591036.001]
  • [Cites] Dtsch Med Wochenschr. 1992 Dec 22;117(51-52):1971-5 [1478172.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):989-96 [7842420.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):959-70 [8372948.001]
  • [Cites] Arch Pathol Lab Med. 1992 Oct;116(10):1079-82 [1384457.001]
  • [Cites] J Obstet Gynaecol Res. 2001 Aug;27(4):231-5 [11721736.001]
  • [Cites] Hautarzt. 2000 Jul;51(7):479-85 [10969401.001]
  • [Cites] Cancer. 1975 Feb;35(2):534-9 [1167482.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):439-43 [11989602.001]
  • (PMID = 14740131.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Song SY, Ko YH, Ahn G: Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association. Int J Surg Pathol; 2005 Jul;13(3):299-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal germ cell tumor associated with histiocytic sarcoma of spleen: case report of an unusual association.
  • We present an unusual association of mediastinal germ cell tumor containing seminoma and angiosarcoma components and splenic histiocytic sarcoma.
  • Histopathologically, an anterior mediastinal mass contained typical seminoma, immature teratoma, embryonal carcinoma, angiosarcoma, yolk sac tumor, and polyembryoma.
  • An abdominal ultrasonogram revealed a huge splenomegaly with multiple ill-defined low echogenic nodules, 1 month after the second cycle of chemotherapy.
  • [MeSH-major] Hemangiosarcoma / pathology. Histiocytic Sarcoma / pathology. Mediastinal Neoplasms / pathology. Seminoma / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Neoplasms, Multiple Primary. Splenomegaly. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086090.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


24. Locke JE, Barber LG: Comparative aspects and clinical outcomes of canine renal hemangiosarcoma. J Vet Intern Med; 2006 Jul-Aug;20(4):962-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative aspects and clinical outcomes of canine renal hemangiosarcoma.
  • BACKGROUND: Hemangiosarcoma (HSA) is a common solid tumor of the spleen, heart, and skin of dogs.
  • METHODS: Medical records from 1999 to 2004 were searched for dogs with histopathologically confirmed renal HSA, and data relevant to clinical signs, treatments, and outcomes were abstracted.
  • RESULTS: Clinical signs were nonspecific, and the median duration of clinical signs before diagnosis was 60 days.
  • One dog had pulmonary metastasis at diagnosis.
  • All dogs underwent nephrectomy, and 4/14 dogs also received adjunctive chemotherapy.
  • Median survival time of all dogs was 278 days (range 0-1,005 days), and dogs with hemoperitoneum had significantly shorter survival times than dogs without hemoperitoneum (62 days versus 286 days, P < .001).
  • CONCLUSIONS AND CLINICAL IMPORTANCE: These results indicate that hemoperitoneum and distant metastasis at diagnosis appear to occur less frequently in dogs with renal HSA compared with other visceral forms of HSA.
  • Furthermore, dogs with renal HSA have protracted disease progression, with improved 1-year survival rates and longer median survival time compared to dogs with splenic, cardiac, and retroperitoneal HSA.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955823.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement